Hyperlysinemia
Ultimo aggiornamento 26 Giugno 2025
Rispetta le linee guida editoriali
- ScaricaScarica
- Condividi
- Language
- Discussione
- Ask Patient
- Versione audio
- Aggiungi alle fonti preferite su Google
Hyperlysinemia is an inherited condition that is characterised by elevated blood levels of lysine, which is one of the building blocks (amino acids) of proteins. Amino acids are not stored in the body and must be broken down when they are no longer needed. When the body's ability to break down lysine is impaired, lysine can build up and cause hyperlysinemia. Hyperlysinemia is classified as either type I or type II, depending on which steps of lysine breakdown are interrupted.
Scelte video per Condizioni geneticheVideo library
Descrizione
Hyperlysinemia is an inherited condition that is characterised by elevated blood levels of lysine, which is one of the building blocks (amino acids) of proteins. Amino acids are not stored in the body and must be broken down when they are no longer needed. When the body's ability to break down lysine is impaired, lysine can build up and cause hyperlysinemia. Hyperlysinemia is classified as either type I or type II, depending on which steps of lysine breakdown are interrupted.
The signs and symptoms of hyperlysinemia can vary widely, even among members of the same family. The features that have been reported in people with hyperlysinemia have included short stature, speech and language delays, intellectual disabilities, behavioural abnormalities, abnormal muscle stiffness (spasticity), and seizures. However, some researchers have suggested that as many as half of all people with hyperlysinemia are asymptomatic, which means that they do not have any signs or symptoms of the disorder. These people may not even be aware that they have the condition.
Because the signs and symptoms of hyperlysinemia can vary and because hyperlysinemia is very rare, it is difficult for researchers to determine whether these features are caused by the condition itself or by other factors.
People with a condition called 2,4-dienoyl-CoA reductase (DECR) deficiency may also have hyperlysinemia. Additional features of DECR deficiency may include an inability to grow and gain weight as expected (failure to thrive), developmental delays, abnormal brain function (encephalopathy), and eye abnormalities such as degeneration of the nerves that carry information from the eyes to the brain (optic atrophy).
Modelli di ereditarietà
The source lists the following possible inheritance patterns: Autosomal recessive. More than one pattern can apply in different cases.
Related genes
Altri nomi
Alpha-aminoadipic semialdehyde synthase deficiency
Familial hyperlysinemia
Lysine alpha-ketoglutarate reductase deficiency
Saccharopine dehydrogenase deficiency
Saccharopinuria
Ulteriori letture e riferimenti
- Hyperlysinemia; MedlinePlus, National Library of Medicine.
- Houten SM, Denis S, Te Brinke H, Jongejan A, van Kampen AH, Bradley EJ, Baas F, Hennekam RC, Millington DS, Young SP, Frazier DM, Gucsavas-Calikoglu M, Wanders RJ. Mitochondrial NADP(H) deficiency due to a mutation in NADK2 causes dienoyl-CoA reductase deficiency with hyperlysinemia. Hum Mol Genet. 2014 Sep 15;23(18):5009-16. doi: 10.1093/hmg/ddu218. Epub 2014 May 8.
- Houten SM, Te Brinke H, Denis S, Ruiter JP, Knegt AC, de Klerk JB, Augoustides-Savvopoulou P, Haberle J, Baumgartner MR, Coskun T, Zschocke J, Sass JO, Poll-The BT, Wanders RJ, Duran M. Genetic basis of hyperlysinemia. Orphanet J Rare Dis. 2013 Apr 9;8:57. doi: 10.1186/1750-1172-8-57.
- Marinella G, Pascarella F, Vetro A, Bonuccelli A, Pochiero F, Santangelo A, Alessandri MG, Pasquariello R, Orsini A, Battini R. Hyperlysinemia, an ultrarare inborn error of metabolism: Review and update. Seizure. 2024 Aug;120:135-141. doi: 10.1016/j.seizure.2024.06.020. Epub 2024 Jun 24.
- Markovitz PJ, Chuang DT, Cox RP. Familial hyperlysinemias. Purification and characterization of the bifunctional aminoadipic semialdehyde synthase with lysine-ketoglutarate reductase and saccharopine dehydrogenase activities. J Biol Chem. 1984 Oct 10;259(19):11643-6.
- Pomerantz DJ, Ferdinandusse S, Cogan J, Cooper DN, Reimschisel T, Robertson A, Bican A, McGregor T, Gauthier J, Millington DS, Andrae JLW, Tschannen MR, Helbling DC, Demos WM, Denis S, Wanders RJA, Newman JN, Hamid R, Phillips JA 3rd; Collaborators of UDN. Clinical heterogeneity of mitochondrial NAD kinase deficiency caused by a NADK2 start loss variant. Am J Med Genet A. 2018 Mar;176(3):692-698. doi: 10.1002/ajmg.a.38602. Epub 2018 Feb 1.
- Sacksteder KA, Biery BJ, Morrell JC, Goodman BK, Geisbrecht BV, Cox RP, Gould SJ, Geraghty MT. Identification of the alpha-aminoadipic semialdehyde synthase gene, which is defective in familial hyperlysinemia. Am J Hum Genet. 2000 Jun;66(6):1736-43. doi: 10.1086/302919. Epub 2000 Apr 20.
- Saudubray JM, Rabier D. Biomarkers identified in inborn errors for lysine, arginine, and ornithine. J Nutr. 2007 Jun;137(6 Suppl 2):1669S-1672S. doi: 10.1093/jn/137.6.1669S.
- Tondo M, Calpena E, Arriola G, Sanz P, Martorell L, Ormazabal A, Castejon E, Palacin M, Ugarte M, Espinos C, Perez B, Perez-Duenas B, Perez-Cerda C, Artuch R. Clinical, biochemical, molecular and therapeutic aspects of 2 new cases of 2-aminoadipic semialdehyde synthase deficiency. Mol Genet Metab. 2013 Nov;110(3):231-6. doi: 10.1016/j.ymgme.2013.06.021. Epub 2013 Jul 6.
- van Gelderen HH, Teijema HL. Hyperlysinaemia. Harmless inborn error of metabolism? Arch Dis Child. 1973 Nov;48(11):892-5. doi: 10.1136/adc.48.11.892. No abstract available.
- Yeganeh M, Auray-Blais C, Maranda B, Sabovic A, DeVita RJ, Lazarus MB, Houten SM. A case of hyperlysinemia identified by urine newborn screening. JIMD Rep. 2023 Oct 22;64(6):440-445. doi: 10.1002/jmd2.12399. eCollection 2023 Nov.
Storia dell'articolo
Articolo disponibile anche in Inglese, Tedesco, Spagnolo, Francese, Italiano, Portoghese, Hindi, Ebraico, Arabo, and Svedese.
26 Giugno 2025 | Ultima versione
1 giu 2025 | Pubblicato originariamente
Condividi i tuoi pensieri o esperienze con gli altri nel nostro comunità di pazienti.
Iscriviti alla newsletter di Patient
La tua dose settimanale di consigli sulla salute chiari e affidabili - scritti per aiutarti a sentirti informato, sicuro e in controllo.
Abbonandoti accetti i nostri Informativa sulla Privacy. Puoi annullare l'iscrizione in qualsiasi momento. Non vendiamo mai i tuoi dati.

